KPV vs TB-500
KPV (Alpha-MSH-derived tripeptide fragment) and TB-500 (Actin-binding peptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | KPV | TB-500 |
|---|---|---|
| Compound class | Alpha-MSH-derived tripeptide fragment | Actin-binding peptide fragment |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 3 amino acids | 7 amino acids |
| Molecular weight | 342.43 g/mol | ~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form |
| Half-life | Not documented | ~2-3 hours (elimination); tissue effects reported to persist for days |
| Origin | KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin peptide. It is studied as a fragment that retains some anti-inflammatory properties of the parent hormone. | TB-500 is a synthetic peptide commonly described as corresponding to the actin-binding domain (a short fragment, often the LKKTETQ region) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is produced synthetically and is not identical to full-length Thymosin Beta-4. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How KPV works
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
How TB-500 works
Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
KPV
TB-500
What sets each apart
KPV
KPV is distinguished by its melanocortin-pathway anti-inflammatory focus, in contrast to the antimicrobial LL-37 or the tissue-repair emphasis of BPC-157 and TB-500.
TB-500
TB-500 is defined by its actin-binding fragment identity, distinguishing it from BPC-157's growth-factor/angiogenesis focus and from copper tripeptides used cosmetically.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
How does KPV produce anti-inflammatory effects without affecting pigmentation?
KPV corresponds only to the C-terminal tripeptide of alpha-MSH, so it preserves the anti-inflammatory activity associated with that region while omitting the sequence needed to activate melanocortin receptors that drive pigmentation. Mechanistically it is described as acting intracellularly on the NF-kB pathway, including inhibition of IkB kinase.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is a research peptide associated with thymosin beta-4 (Tbeta4), a 43-amino-acid actin-binding regulatory peptide. The name TB-500 is used in the research-chemical market for both full-length thymosin beta-4 (MW ~4921 Da) and, in some references, the acetylated active fragment covering residues 17-23 (Ac-LKKTETQ). Buyers should check each vendor's COA, since what is shipped as 'TB-500' varies.
What is TB-500 studied for?
In animal models it is researched for tissue repair, wound healing, angiogenesis, and cell migration, largely through thymosin beta-4's role in sequestering G-actin and regulating the actin cytoskeleton. It has also been examined in cardiac and corneal repair models. Human clinical efficacy has not been established.
What does TB-500's half-life imply for research protocols?
Reported elimination half-life is roughly 2-3 hours, but downstream tissue effects are described as persisting for days through signaling cascades. Because of this, research protocols typically use infrequent dosing (e.g. a few times per week) rather than daily, loading over several weeks before a maintenance phase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.